Maple syrup urine disease (MSUD) — classic + intermediate + intermittent + thiamine-responsive variants

What changes during this transition

Maple syrup urine disease (MSUD) is an autosomal recessive disorder of branched-chain amino acid catabolism caused by deficiency of the branched-chain α-ketoacid dehydrogenase complex (BCKDC) — the mitochondrial enzyme complex required to catabolize the three branched-chain amino acids leucine, isoleucine, and valine. The clinical population a peptide companion engages with sits across multiple genetic etiologies and phenotypic severities. BCKDHA encodes the E1α subunit, BCKDHB encodes the E1β subunit, DBT encodes the E2 dihydrolipoyl transacylase subunit, DLD encodes the E3 dihydrolipoyl dehydrogenase subunit (shared with the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes, so DLD deficiency carries a distinct combined-deficiency phenotype), PPM1K encodes the phosphatase, and BCKDK encodes the kinase that regulates the complex. Classic MSUD accounts for roughly 85% of cases and is the editorial center of gravity: presentation in the first days to weeks of life with poor feeding, lethargy, progressive encephalopathy, opisthotonus, and the characteristic maple-syrup-smelling urine from branched-chain α-keto acid metabolites; untreated, classic MSUD progresses to coma, cerebral edema, and death within weeks. Intermediate, intermittent, and thiamine-responsive MSUD variants present later with milder phenotypes and can be missed until a metabolic stressor — infection, surgery, fasting — precipitates a first decompensation in adolescence or adulthood. Mennonite and Amish founder populations in Lancaster County PA and the broader Old Order Amish carry the highest known MSUD prevalence at roughly 1 in 175 births via a distinct BCKDHA founder mutation — the population concentration is what made the Clinic for Special Children in Strasburg PA, anchored by D. Holmes Morton and Kevin Strauss, the world-leading clinical and research center for MSUD. Diagnosis was transformed by newborn screening: MSUD was added to the US Recommended Uniform Screening Panel and is now universally screened across all US states by tandem mass spectrometry detection of elevated leucine in the first days of life, catching classic MSUD before the first decompensation. Standard-of-care for classic MSUD is the LIFELONG STRICT LEUCINE-RESTRICTED DIET, anchored by limited natural protein and BCAA-free medical formula (Mead Johnson BCAD 1 and BCAD 2; Nutricia MSUD Anamix Infant, Junior, and adult formulas) that provides all amino acids EXCEPT leucine, isoleucine, and valine. Plasma leucine is the central monitoring variable, with age-specific target ranges, and alloisoleucine is a pathognomonic marker. Thiamine in pharmacologic doses is used in thiamine-responsive subtypes. Acute decompensation — driven by infection, fasting, surgery, or any catabolic stressor — is a metabolic emergency: hemodialysis or continuous renal replacement therapy (CRRT) to remove BCAAs from plasma, intralipid plus dextrose to drive protein anabolism, and emergency protein restriction. Liver transplantation became a genuinely curative option for severe classic MSUD in the 2004 Strauss/Morton Clinic for Special Children pediatric cohort — restored hepatic BCKDC activity is enough to remove the lifelong dietary restriction, with patients transitioning from strict every-meal protein measurement to an unrestricted diet. This distinguishes MSUD from cystinosis (substrate batch 158), where renal transplantation does NOT cure the systemic lysosomal defect because the defect is in the patient's lysosomes everywhere; in MSUD, restoring BCKDC activity in the liver supplies enough whole-body catabolic capacity that the diet comes off. Domino liver transplantation — where an MSUD patient's liver is used as a donor organ for a non-MSUD recipient, because the MSUD liver functions normally for everything except BCAA catabolism — is a niche but real practice that extends the cadaveric organ pool. The patient infrastructure is multi-jurisdictional: MSUD Family Support Group (msudfamilysupportgroup.org) and the MSUD Research Foundation are the main US patient organizations; the Clinic for Special Children in Strasburg PA is the world-leading MSUD center; the European MSUD network covers the rest. No peptide in the Juno library has a discovery-card-defensible MSUD case. BPC-157 reaches the population through the 'tissue repair' and 'gut healing' community framing with the pro-angiogenic VEGF/eNOS mechanism uncharacterized in BCKDC biology and the SC injection schedule colliding with the every-meal strict dietary regimen. NMN reaches the post-transplant adult MSUD cohort through general-aging framing on top of chronic immunosuppression. The GH-axis trio surfaces a real but sharp concern — GH/IGF-1 anabolism drives leucine flux from the catabolism-blocked compartments into plasma, which is exactly the variable the diet and monitoring infrastructure are built to control; somatropin in confirmed pediatric GHD under metabolic-team supervision with explicit leucine-flux planning is the supervised pathway, and tesamorelin Rule 6 non-propagation is sharpest. Semaglutide is the coordination-of-care conversation for adult MSUD with non-transplanted patients carrying a load-bearing protein-substitute adherence risk. Ninety-fifth deliberate non-elevation.